Refractory GERD: What is it?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Refractory gastroesophageal reflux disease (GERD) is very common and may affect up to 40% of patients who use a proton pump inhibitor (PPI) once daily. Refractory GERD can present as incomplete or lack of response to PPI therapy. The disorder is clearly driven by patients, who present with a wide range of symptom severity and frequency while on PPI treatment. Poor compliance and improper timing of PPI consumption should always be excluded before further evaluation of this patient population. The putative mechanisms for refractory GERD include weakly acidic reflux, duodenogastroesophageal/bile reflux, visceral hypersensitivity, delayed gastric emptying, psychological comorbidity, and concomitant functional bowel disorders. Reduced PPI bioavailability, rapid PPI metabolism, PPI resistance, nocturnal reflux, and Helicobacter pylori infection status have very limited roles in refractory GERD. The contribution of eosinophilic esophagitis to refractory GERD is still unknown. Pill-induced esophagitis, Zollinger-Ellison syndrome, achalasia, and other disorders are rarely responsible for PPI failure and usually are not confused with GERD.
- Fass R, Shapiro M, Dekel R, Sewell J: Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease—where next? Aliment Pharmacol Ther 2005, 22:79–94. CrossRef
- Targownik LE, Metge C, Roos L, Leung S: The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. Am J Gastroenterol 2007, 102:942–950. CrossRef
- Crawley JA, Schmitt CM: How satisfied are chronic heartburn sufferers with their prescription medications? Rules of the Patient Unmet Needs Survey. J Clin Outcomes Manag 2000, 7:29–34.
- Dean BB, Gano AD Jr, Knight K, et al.: Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004, 2:656–664. CrossRef
- Lind T, Havelund T, Carlsson R, et al.: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997, 32:974–979. CrossRef
- Richter JE, Kahrilas PJ, Johanson J, et al.: Efficacy and safety of esomeprazole compared to omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001, 96:656–665. CrossRef
- Johnson DA, Lauritsen K, Junghard O, Levine D: Evaluation of symptoms is an unreliable predictor of relapse of erosive esophagitis in patients receiving maintenance PPI therapy [abstract T1646]. Gastroenterology 2003, 124(4 Suppl):A540. CrossRef
- Gunaratnam NT, Jessup TP, Inadomi JM, Lascewski DP: Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006, 23:1473–1477. CrossRef
- Vela M, Camacho-Lobato L, Srinivasan R, et al.: Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001, 120:1599–1606. CrossRef
- Mainie I, Tutuian R, Shay S, et al.: Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy. A multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006, 55:1398–1402. CrossRef
- Martinez SD, Malagon IB, Garewal HS, et al.: Non-erosive reflux disease (NERD)—acid reflux and symptom patterns. Aliment Pharmacol Ther 2003, 17:537–545. CrossRef
- Shapiro M, Green C, Bautista J, et al.: Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J Gastroenterol 2006, 101:1084–1091. CrossRef
- Vaezi MF: Duodenogastroesophageal reflux. In The Oesophagus, edn 4. Edited by Castro D, Richter J. Philadelphia: Lippincott Williams & Wilkins; 2004:1553–1558.
- Tack J, Koek G, Demedts I, et al.: Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004, 99:981–988. CrossRef
- Kudara N, Chiba T, Orii S, Suzuki K: Gastric emptying of patients with persistent reflux symptoms and erosive esophagitis under PPI therapy [abstract 23]. Neurogastroenterol Motil 2004, 16:654.
- Jansson C, Nordenstedt H, Wallander MA, et al.: Severe gastro-oesophageal reflux symptoms in relation to anxiety, depression and coping in a population-based study. Aliment Pharmacol Ther 2007, 26:683–691. CrossRef
- Rubenstein JH, Nojkov B, Korsnes S, et al.: Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther 2007, 26:443–452.
- Delhotal-Landes B, Cournot A, Vermerie N, et al.: The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet 1991, 3:315–320.
- Fass R, Murthy U, Hayden CW, et al.: Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy—a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000, 14:1595–1603. CrossRef
- Dammann HG, Fuchs W, Richter G, et al.: Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther 1997, 11:359–364. CrossRef
- Leite L, Lambrecht N, Sachs G, et al.: Is omeprazole resistance due to mutations of cysteine 813 or 822 in the acid pump [abstract]? Gastroenterology 1995, 108:A147.
- Furuta T, Shirai N, Watanabe F, et al.: Effect of cytochrome P4502C19 genotypic differences on cure rates for gastro-esophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002, 72:453–460. CrossRef
- Kawamura M, Ohara S, Koike T, et al.: The effect of lansoprazole on erosive reflux esophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003, 17:965–973. CrossRef
- Egan LJ, Myhre GM, Mays DC, et al.: CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther 2003, 17:1521–1528. CrossRef
- Verdu EF, Armstrong D, Fraser R, et al.: Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995, 36:539–543. CrossRef
- Vigneri S, Termini R, Savarino V, Pace F: Review article: is Helicobacter pylori status relevant to the management of GORD? Aliment Pharmacol Ther 2000, 14(Suppl 3):31–42. CrossRef
- Holtmann G, Cain C, Malfertheiner P: Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999, 117:11–16. CrossRef
- Refractory GERD: What is it?
Current Gastroenterology Reports
Volume 10, Issue 3 , pp 252-257
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links